Investigating the Pharmacokinetic and Pharmacodynamic Profiles Following Continuous Subcutaneous Infusion of Insulin Aspart or Injection of Insulin Glargine in Subjects With Type 2 Diabetes Mellitus.

Trial Profile

Investigating the Pharmacokinetic and Pharmacodynamic Profiles Following Continuous Subcutaneous Infusion of Insulin Aspart or Injection of Insulin Glargine in Subjects With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Insulin aspart; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 16 Jun 2009 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 11 Jun 2009 Actual number of patients changed from 21 to 22 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top